Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIVALO HI (JW Theriac Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Kowa Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LIVALO HI is an oral fixed-dose small-molecule combination product from JW Theriac that combines pitavastatin, valsartan, and amlodipine for simultaneous management of hyperlipidemia and hypertension. The regimen pairs **HMG-CoA reductase inhibition** from pitavastatin to lower LDL cholesterol with **angiotensin II receptor blockade** from valsartan and **L-type calcium channel blockade** from amlodipine to reduce blood pressure, making it a cardiovascular risk-reduction combination for patients requiring both lipid lowering and antihypertensive therapy. JW Theriac's pipeline lists LIVALO HI as an approved product, with multiple tablet strengths reported.
- Brand names
- LIVALO HI
- Other names
- pitavastatin + valsartan + amlodipine
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on LIVALO HI (JW Theriac Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIVALO HI (JW Theriac Pharmaceutical).